Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ebos GroupEBOSF +15.85%87 EV-to-Revenue is 0.37 as of Sep. 13, 2026, which is 34% below its 10-year median of 0.56. GuruFocus rates EBOSF with a GF Score™ of 87/100 and a GF Value™ of $46.78. The stock has 5 warning signs investors should review. Among 123 Medical Distribution companies, Ebos Group ranks better than 66.67% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ebos Group's enterprise value is $3,551 Mil.
Ebos Group's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was $9,489 Mil. Therefore, Ebos Group's EV-to-Revenue for today is 0.37.
The historical rank and industry rank for Ebos Group's EV-to-Revenue or its related term are showing as below:
EBOSF'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.37 Med: 0.56 Max: 0.79
Current: 0.37
During the past 13 years, the highest EV-to-Revenue of Ebos Group was 0.79. The lowest was 0.37. And the median was 0.56.
EBOSF's EV-to-Revenue is ranked better than 66.67% of 123
companies
in the Medical Distribution industry
Industry Median: 0.59
vs EBOSF: 0.37
As of today (2026-09-13), Ebos Group's stock price is $23.75.
Ebos Group's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $45.97. Therefore, Ebos Group's PS Ratio for today is 0.52.
Ebos Group's share price for today is $23.75.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2026 was $45.97.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ebos Group EV-to-Revenue Related Terms
Ebos Group EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for Ebos Group's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Ebos Group's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group EV-to-Revenue vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Ebos Group's EV-to-Revenue falls into.
Ebos Group's current Enterprise Value is $3,551 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ebos Group's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was $9,489 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ebos Group (EBOSF) has a EV-to-Revenue of 0.37 as of Sep. 13, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Ebos Group and its competitors. This is 34% below median its historical median of 0.56. Over the past decade, Ebos Group's EV-to-Revenue has ranged from 0.37 to 0.79. According to the industry distribution chart, Ebos Group ranks #41 out of 123 companies in the Medical Distribution industry, placing it in the top 33.3%.
Is Ebos Group's EV-to-Revenue too high?
Ebos Group's current EV-to-Revenue of 0.37 is 34% below median its 10-year median of 0.56. Over the past 10 years, this metric has ranged from a low of 0.37 to a high of 0.79. The Medical Distribution industry median EV-to-Revenue is 0.59. Ebos Group's value of 0.37 is 37.3% below this industry median. Based on the distribution chart, Ebos Group ranks #41 out of 123 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Ebos Group has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's EV-to-Revenue compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #41 out of 123 companies for EV-to-Revenue. This puts Ebos Group in the upper half of its industry. The industry median EV-to-Revenue is 0.59. Ebos Group's value of 0.37 is 37.3% below this benchmark. Historically, Ebos Group's own EV-to-Revenue has ranged from 0.37 to 0.79 over the past decade. While the company's 10-year median is 0.56 vs. the industry median of 0.59, Ebos Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Medical Distribution company?
The median EV-to-Revenue among Medical Distribution companies is 0.59, based on 123 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current EV-to-Revenue of 0.37 is 37.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Ebos Group and its competitors. For the Medical Distribution industry, the median EV-to-Revenue is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current EV-to-Revenue is 0.37, which is 34% below median its own 10-year median of 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Ebos Group (EBOSF) has a current EV-to-Revenue of 0.37. The stock's GF Value™ is $46.78, compared to a current price of $23.75 — trading 49.2% below its estimated fair value. The current EV-to-Revenue is 0.37, which is 34% below median its 10-year median of 0.56 and 37.3% below the Medical Distribution industry median of 0.59. Ebos Group's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For Ebos Group (EBOSF), the current EV-to-Revenue is 0.37 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (EBOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of $23.75 is trading 49.2% below its estimated GF Value™ of $46.78.
Key valuation signals for EBOSF:
EV-to-Revenue: 0.37 (34% below median its 10-year median of 0.56)
GF Value™: $46.78 vs. price of $23.75 (49.2% below fair value)
Industry Position: 37.3% below the Medical Distribution median (#41 of 123)
No single metric tells the full story. See the EBOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
87GF Score
Get the complete analysis for EBOSF
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EBOSF has been successfully added to your 
